This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
The Zacks Analyst Blog Highlights: Amazon, UnitedHealth, AbbVie, Simon Property and Autodesk
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon, UnitedHealth, AbbVie, Simon Property and Autodesk
AbbVie (ABBV) Shares Down So Far This Year: Here's Why
by Zacks Equity Research
AbbVie's (ABBV) stock suffers a poor run on the bourses due to pipeline setbacks, Humira sales erosion in EU and its proposed offer to buy Allergan.
Are You Looking for a High-Growth Dividend Stock? AbbVie (ABBV) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
Top Stock Reports for Amazon, UnitedHealth & AbbVie
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amazon (AMZN), UnitedHealth (UNH) and AbbVie (ABBV).
Will the Pharma Space Witness More Mega-Merger Deals in 2H?
by Kinjel Shah
After two mega-mergers, Bristol-Myers/Celgene and AbbVie/Allergan, in first half of 2019, it remains to be seen if more such deals are in store for the second half.
Gilead to Submit NDA for Inflammation Drug Filgotinib in '19
by Zacks Equity Research
Gilead (GILD) is planning to submit regulatory application to the FDA seeking approval for filgotinib as a treatment for rheumatoid arthritis.
AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $73.40 in the latest trading session, marking a +0.94% move from the prior day.
Pfizer's (PFE) Avastin Biosimilar Zirabev Gets FDA Approval
by Zacks Equity Research
Pfizer (PFE) gets FDA approval for biosimilar Avastin, Zirabev. This is Pfizer's second oncology biosimilar to be approved in United States.
Pharma Stock Roundup: ABBV to Buy AGN, BMY to Sell CELG's Otezla to Close Merger
by Kinjel Shah
AbbVie (ABBV) announces definitive deal to buy Allergan (AGN). Bristol-Myers (BMY) set to sell Celgene's Otezla to complete the impending merger.
Is Allergan a Good Deal for AbbVie?
by Sejuti Banerjea
AbbVie is dishing out $63 billion in stock and cash for Allergan, provided it gets regulatory approval.
AbbVie to Buy Allergan: Prescribed ETFs
by Sweta Killa
AbbVie has agreed to buy Botox-maker Allergan for $63 billion in a cash-and-stock deal. The news has put the spotlight on a number of healthcare ETFs.
Company News For Jun 26, 2019
by Zacks Equity Research
Companies in the news are: ABBV, AGN, LEN, XNCR, USNA and LION
AbbVie to Acquire Allergan in Nearly $62B Cash & Stock Deal
by Zacks Equity Research
AbbVie (ABBV) offers nearly $63 billion to acquire Botox-maker Allergan to diversify its product portfolio.
The Zacks Analyst Blog Highlights: AbbVie, Allergan, Bristol-Myers and Celgene
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, Allergan, Bristol-Myers and Celgene
AbbVie + Allergan: Where Are The Synergies?
by Daniel Laboe
AbbVie (ABBV) is on the hunt for their next big revenue driver as their patent for the world???s top-selling drug, Humira, is nearing its end. AbbVie just made a $63 billion deal to acquire Dublin-based Allergan (AGN) in an attempt to keep their drive alive.
AbbVie (ABBV) Stock Falls After $63 Billion Allergan Acquisition Announcement
by Zachary Stutler
AbbVie announced Tuesday morning its intent to acquire Allergan for $63 billion.
Abbvie Decides to Acquire Allergan
by Zacks Equity Research
Abbvie Decides to Acquire Allergan
AbbVie to Buy Botox-Maker Allergan, Look Ahead to G-20
by Mark Vickery
AbbVie (ABBV) has agreed to purchase Botox maker Allergan (AGN) for roughly $63 billion in cash and stock.
AbbVie Announces Lifting of FDA's Partial Hold on CANOVA Study
by Zacks Equity Research
AbbVie (ABBV) receives encouraging news as FDA lifts partial clinical hold on a late-stage study evaluating Venclexta in relapsed/refractory multiple myeloma.
Zacks.com featured highlights include: Crocs, Brinker, Shoe Carnival, AbbVie and Criteo
by Zacks Equity Research
Zacks.com featured highlights include: Crocs, Brinker, Shoe Carnival, AbbVie and Criteo
AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $78.45 in the latest trading session, marking a -0.42% move from the prior day.
Forget Bargain Hunting: Tap 5 Stocks With Rising P/E
by Sanghamitra Saha
Bet on these top-ranked stocks with rising P/E to realize outsized gains.
Novo Nordisk's Haemophilia A Drug Esperoct Gets EU Approval
by Zacks Equity Research
Novo Nordisk's (NVO) Esperoct gets EU approval for the treatment of adolescents (less-than or equal-to 12 years of age) and adults with haemophilia A.
Sanofi/Regeneron's Asthma Candidate Meets Goal in Study
by Zacks Equity Research
Sanofi/Regeneron's IL-33 antibody REGN3500 meets primary endpoint in phase II study in asthma. It does not show increased benefit compared to Dupixent.
Top Ranked Income Stocks to Buy for June 21st
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, June 21st.